GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

Genzyme Gains Marketing Rights for Ceregene’s Parkinson's Drug in $150M Deal

  • Ceregene and Genzyme entered into a partnership for the development and commercialization of Ceregene's Phase II candidate, CERE-120, for the treatment of Parkinson's disease.

    Under the terms of the agreement, Genzyme will pay Ceregene $25 million upfront in exchange for certain partnership-related expenses. Ceregene also is entitled to development-related milestone payments of up to $125 million and 50% reimbursement of the worldwide Phase III development costs.

    Genzyme will gain marketing rights in all areas outside the U.S. and Canada and will pay Ceregene tiered sales royalties.  Ceregene thus retains exclusive rights in the U.S. and Canada.

    “The resources provided by our new partnership with Genzyme, together with the greater than $27-million initial closing of our Series C financing, provides the funding we currently need to advance CERE-120 toward commercialization," points out Jeffrey M. Ostrove, Ph.D., president and CEO of Ceregene.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?